PCVX
Vaxcyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$65.68
+8.01%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$62.87
From 52W high−11.03%
Volume2.24M
Market cap$10.34B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$62.87
From 52W high
−11.03%
Volume
2.24M
Market cap
$10.34B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.5x
P/E (TTM)
—
RSI (14)
47.9
MomentumView details →
1D Return
+8.01%
YTD Return
+33.14%
SummaryUpdated Jun 1, 2026
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company founded in 2013 and headquartered in San Carlos, California. Originally incorporated as SutroVax, Inc., the company rebranded to Vaxcyte in May 2020 and went public in June 2020. Vaxcyte specializes in developing novel protein vaccines designed to prevent or treat bacterial infectious diseases, with a particular focus on pneumococcal infections and other serious bacterial pathogens that pose significant public health challenges.
Similar companies
Latest newsMore news →
Vaxcyte announced positive topline results from the OPUS-1 pivotal Phase 3 trial of VAX-31 for adults, reporting that it met all prespecified primary endpoints, was well tolerated and had a safety profile similar to PCV20 and PCV21 across the ages studied.51m agoVaxcyte reported third-quarter 2026 financial results and said pro forma cash, cash equivalents and investments were approximately $3.4 billion as of September 30, including approximately $1.1 billion in net proceeds from October equity and convertible senior notes offerings.51m agoVaxcyte, Inc. agreed to issue $575 million of 1.50% convertible senior notes due 2032, including a $75 million over-allotment option exercised in full.26d ago